These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

322 related items for PubMed ID: 22707609

  • 1. Effect of belimumab on vaccine antigen antibodies to influenza, pneumococcal, and tetanus vaccines in patients with systemic lupus erythematosus in the BLISS-76 trial.
    Chatham WW, Wallace DJ, Stohl W, Latinis KM, Manzi S, McCune WJ, Tegzová D, McKay JD, Avila-Armengol HE, Utset TO, Zhong ZJ, Hough DR, Freimuth WW, Migone TS, BLISS-76 Study Group.
    J Rheumatol; 2012 Aug; 39(8):1632-40. PubMed ID: 22707609
    [Abstract] [Full Text] [Related]

  • 2. Immune responses following administration of influenza and pneumococcal vaccines to patients with rheumatoid arthritis receiving adalimumab.
    Kaine JL, Kivitz AJ, Birbara C, Luo AY.
    J Rheumatol; 2007 Feb; 34(2):272-9. PubMed ID: 17304653
    [Abstract] [Full Text] [Related]

  • 3. Belimumab reduces autoantibodies, normalizes low complement levels, and reduces select B cell populations in patients with systemic lupus erythematosus.
    Stohl W, Hiepe F, Latinis KM, Thomas M, Scheinberg MA, Clarke A, Aranow C, Wellborne FR, Abud-Mendoza C, Hough DR, Pineda L, Migone TS, Zhong ZJ, Freimuth WW, Chatham WW, BLISS-52 Study Group, BLISS-76 Study Group.
    Arthritis Rheum; 2012 Jul; 64(7):2328-37. PubMed ID: 22275291
    [Abstract] [Full Text] [Related]

  • 4. Immunization responses in rheumatoid arthritis patients treated with rituximab: results from a controlled clinical trial.
    Bingham CO, Looney RJ, Deodhar A, Halsey N, Greenwald M, Codding C, Trzaskoma B, Martin F, Agarwal S, Kelman A.
    Arthritis Rheum; 2010 Jan; 62(1):64-74. PubMed ID: 20039397
    [Abstract] [Full Text] [Related]

  • 5. Belimumab: review of use in systemic lupus erythematosus.
    Boyce EG, Fusco BE.
    Clin Ther; 2012 May; 34(5):1006-22. PubMed ID: 22464040
    [Abstract] [Full Text] [Related]

  • 6. Disease control and safety of belimumab plus standard therapy over 7 years in patients with systemic lupus erythematosus.
    Ginzler EM, Wallace DJ, Merrill JT, Furie RA, Stohl W, Chatham WW, Weinstein A, McKay JD, McCune WJ, Zhong ZJ, Freimuth WW, Petri MA, LBSL02/99 Study Group.
    J Rheumatol; 2014 Feb; 41(2):300-9. PubMed ID: 24187095
    [Abstract] [Full Text] [Related]

  • 7. A randomized, open-label study to investigate the effect of belimumab on pneumococcal vaccination in patients with active, autoantibody-positive systemic lupus erythematosus.
    Chatham W, Chadha A, Fettiplace J, Kleoudis C, Bass D, Roth D, Gordon D.
    Lupus; 2017 Dec; 26(14):1483-1490. PubMed ID: 28467293
    [Abstract] [Full Text] [Related]

  • 8. Vaccine responses in patients with rheumatoid arthritis treated with certolizumab pegol: results from a single-blind randomized phase IV trial.
    Kivitz AJ, Schechtman J, Texter M, Fichtner A, de Longueville M, Chartash EK.
    J Rheumatol; 2014 Apr; 41(4):648-57. PubMed ID: 24584918
    [Abstract] [Full Text] [Related]

  • 9. Long-term safety profile of belimumab plus standard therapy in patients with systemic lupus erythematosus.
    Merrill JT, Ginzler EM, Wallace DJ, McKay JD, Lisse JR, Aranow C, Wellborne FR, Burnette M, Condemi J, Zhong ZJ, Pineda L, Klein J, Freimuth WW, LBSL02/99 Study Group.
    Arthritis Rheum; 2012 Oct; 64(10):3364-73. PubMed ID: 22674457
    [Abstract] [Full Text] [Related]

  • 10. Treatment with belimumab in systemic lupus erythematosus does not impair antibody response to 13-valent pneumococcal conjugate vaccine.
    Nagel J, Saxne T, Geborek P, Bengtsson AA, Jacobsen S, Svaerke Joergensen C, Nilsson JÅ, Skattum L, Jönsen A, Kapetanovic MC.
    Lupus; 2017 Sep; 26(10):1072-1081. PubMed ID: 28420056
    [Abstract] [Full Text] [Related]

  • 11. Specific antibody response after influenza immunization in systemic lupus erythematosus.
    Abu-Shakra M, Press J, Varsano N, Levy V, Mendelson E, Sukenik S, Buskila D.
    J Rheumatol; 2002 Dec; 29(12):2555-7. PubMed ID: 12465151
    [Abstract] [Full Text] [Related]

  • 12. Effect of a second, booster, influenza vaccination on antibody responses in quiescent systemic lupus erythematosus: an open, prospective, controlled study.
    Holvast A, van Assen S, de Haan A, Huckriede A, Benne CA, Westra J, Palache A, Wilschut J, Kallenberg CG, Bijl M.
    Rheumatology (Oxford); 2009 Oct; 48(10):1294-9. PubMed ID: 19692457
    [Abstract] [Full Text] [Related]

  • 13. Phase III, multicentre, randomised, double-blind, placebo-controlled, 104-week study of subcutaneous belimumab administered in combination with rituximab in adults with systemic lupus erythematosus (SLE): BLISS-BELIEVE study protocol.
    Teng YKO, Bruce IN, Diamond B, Furie RA, van Vollenhoven RF, Gordon D, Groark J, Henderson RB, Oldham M, Tak PP.
    BMJ Open; 2019 Mar 20; 9(3):e025687. PubMed ID: 30898822
    [Abstract] [Full Text] [Related]

  • 14. A phase III, randomized, placebo-controlled study of belimumab, a monoclonal antibody that inhibits B lymphocyte stimulator, in patients with systemic lupus erythematosus.
    Furie R, Petri M, Zamani O, Cervera R, Wallace DJ, Tegzová D, Sanchez-Guerrero J, Schwarting A, Merrill JT, Chatham WW, Stohl W, Ginzler EM, Hough DR, Zhong ZJ, Freimuth W, van Vollenhoven RF, BLISS-76 Study Group.
    Arthritis Rheum; 2011 Dec 20; 63(12):3918-30. PubMed ID: 22127708
    [Abstract] [Full Text] [Related]

  • 15. Immunization with trivalent inactivated influenza vaccine in partially immunized toddlers.
    Englund JA, Walter EB, Gbadebo A, Monto AS, Zhu Y, Neuzil KM.
    Pediatrics; 2006 Sep 20; 118(3):e579-85. PubMed ID: 16950949
    [Abstract] [Full Text] [Related]

  • 16. A phase II, randomized, double-blind, placebo-controlled, dose-ranging study of belimumab in patients with active systemic lupus erythematosus.
    Wallace DJ, Stohl W, Furie RA, Lisse JR, McKay JD, Merrill JT, Petri MA, Ginzler EM, Chatham WW, McCune WJ, Fernandez V, Chevrier MR, Zhong ZJ, Freimuth WW.
    Arthritis Rheum; 2009 Sep 15; 61(9):1168-78. PubMed ID: 19714604
    [Abstract] [Full Text] [Related]

  • 17. Pneumococcal vaccination in patients with systemic lupus erythematosus: A multicenter placebo-controlled randomized double-blind study.
    Grabar S, Groh M, Bahuaud M, Le Guern V, Costedoat-Chalumeau N, Mathian A, Hanslik T, Guillevin L, Batteux F, Launay O, VACCILUP study group.
    Vaccine; 2017 Sep 05; 35(37):4877-4885. PubMed ID: 28784280
    [Abstract] [Full Text] [Related]

  • 18. 13-valent pneumococcal conjugate vaccine given with meningococcal C-tetanus toxoid conjugate and other routine pediatric vaccinations: immunogenicity and safety.
    Martinón-Torres F, Gimenez-Sanchez F, Gurtman A, Bernaola E, Diez-Domingo J, Carmona A, Sidhu M, Sarkozy DA, Gruber WC, Emini EA, Scott DA, 3007 Study Group.
    Pediatr Infect Dis J; 2012 Apr 05; 31(4):392-9. PubMed ID: 22301472
    [Abstract] [Full Text] [Related]

  • 19. Belimumab for the management of systemic lupus erythematosus.
    Lutalo PM, D'Cruz DP.
    Expert Opin Biol Ther; 2012 Jul 05; 12(7):957-63. PubMed ID: 22646798
    [Abstract] [Full Text] [Related]

  • 20. Belimumab for the treatment of systemic lupus erythematosus.
    Jordan N, D'Cruz DP.
    Expert Rev Clin Immunol; 2015 Feb 05; 11(2):195-204. PubMed ID: 25543845
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 17.